822.55
price down icon0.08%   -1.07
 
loading
Schlusskurs vom Vortag:
$823.62
Offen:
$817
24-Stunden-Volumen:
1.76M
Relative Volume:
0.48
Marktkapitalisierung:
$739.75B
Einnahmen:
$49.00B
Nettoeinkommen (Verlust:
$11.11B
KGV:
66.93
EPS:
12.29
Netto-Cashflow:
$-1.27B
1W Leistung:
-6.19%
1M Leistung:
+11.49%
6M Leistung:
+2.10%
1J Leistung:
+11.98%
1-Tages-Spanne:
Value
$812.02
$829.64
1-Wochen-Bereich:
Value
$792.07
$902.50
52-Wochen-Spanne:
Value
$677.09
$972.53

Lilly Eli Co Stock (LLY) Company Profile

Name
Firmenname
Lilly Eli Co
Name
Telefon
(317) 276-2000
Name
Adresse
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Name
Mitarbeiter
47,000
Name
Twitter
@LillyPad
Name
Nächster Verdiensttermin
2024-10-30
Name
Neueste SEC-Einreichungen
Name
LLY's Discussions on Twitter

Vergleichen Sie LLY mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Drug Manufacturers - General icon
LLY
Lilly Eli Co
822.22 739.75B 49.00B 11.11B -1.27B 12.29
Drug Manufacturers - General icon
JNJ
Johnson Johnson
155.21 370.90B 89.33B 21.81B 18.57B 8.99
Drug Manufacturers - General icon
ABBV
Abbvie Inc
195.29 340.25B 57.37B 4.20B 17.83B 2.35
Drug Manufacturers - General icon
NVO
Novo Nordisk Adr
69.23 277.97B 42.09B 14.65B 10.11B 3.2833
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
113.03 222.45B 53.22B 12.86B 14.85B 6.39

Lilly Eli Co Stock (LLY) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-04-28 Herabstufung HSBC Securities Buy → Reduce
2025-04-22 Eingeleitet Cantor Fitzgerald Overweight
2024-12-10 Fortgesetzt BofA Securities Buy
2024-11-15 Eingeleitet Wolfe Research Outperform
2024-10-17 Eingeleitet Bernstein Outperform
2024-09-13 Fortgesetzt Citigroup Buy
2024-08-12 Hochstufung Deutsche Bank Hold → Buy
2024-02-21 Herabstufung DZ Bank Buy → Hold
2024-02-16 Bestätigt Morgan Stanley Overweight
2023-12-21 Herabstufung Daiwa Securities Buy → Outperform
2023-11-09 Eingeleitet Deutsche Bank Hold
2023-10-20 Fortgesetzt UBS Buy
2023-08-09 Hochstufung Jefferies Hold → Buy
2023-07-26 Bestätigt Citigroup Buy
2023-07-14 Eingeleitet HSBC Securities Buy
2023-05-24 Bestätigt BofA Securities Buy
2023-05-24 Bestätigt UBS Buy
2023-03-13 Hochstufung Wells Fargo Equal Weight → Overweight
2023-03-06 Eingeleitet Jefferies Hold
2023-02-15 Herabstufung Societe Generale Hold → Sell
2022-11-18 Eingeleitet Credit Suisse Outperform
2022-09-22 Hochstufung UBS Neutral → Buy
2022-05-23 Eingeleitet SVB Leerink Outperform
2022-04-06 Fortgesetzt Morgan Stanley Overweight
2022-03-10 Eingeleitet Daiwa Securities Outperform
2022-01-21 Hochstufung DZ Bank Hold → Buy
2022-01-03 Bestätigt Bernstein Mkt Perform
2021-12-17 Eingeleitet Goldman Neutral
2021-12-16 Bestätigt BMO Capital Markets Outperform
2021-12-16 Bestätigt BofA Securities Buy
2021-12-09 Fortgesetzt Wells Fargo Equal Weight
2021-11-19 Eingeleitet BMO Capital Markets Outperform
2021-10-11 Hochstufung Berenberg Hold → Buy
2021-09-29 Hochstufung Citigroup Neutral → Buy
2021-08-05 Hochstufung DZ Bank Hold → Buy
2021-07-27 Fortgesetzt Truist Buy
2021-06-24 Bestätigt Cantor Fitzgerald Overweight
2021-01-19 Hochstufung Mizuho Neutral → Buy
2020-12-10 Hochstufung Wolfe Research Peer Perform → Outperform
2020-11-10 Fortgesetzt Bernstein Mkt Perform
2020-09-29 Eingeleitet Berenberg Hold
2020-09-03 Hochstufung Morgan Stanley Equal-Weight → Overweight
2020-06-16 Hochstufung Guggenheim Neutral → Buy
2020-04-21 Herabstufung UBS Buy → Neutral
2020-04-09 Herabstufung Morgan Stanley Overweight → Equal-Weight
2020-02-06 Eingeleitet Mizuho Neutral
2019-12-18 Hochstufung Morgan Stanley Equal-Weight → Overweight
2019-10-17 Fortgesetzt BofA/Merrill Buy
2019-05-28 Eingeleitet Goldman Buy
2019-04-24 Hochstufung Edward Jones Hold → Buy
2019-04-11 Herabstufung Guggenheim Buy → Neutral
2019-03-12 Eingeleitet JP Morgan Overweight
2019-01-23 Eingeleitet UBS Buy
2018-11-26 Herabstufung Citigroup Buy → Neutral
2018-10-31 Hochstufung Credit Suisse Underperform → Neutral
2018-10-09 Eingeleitet Guggenheim Buy
2018-10-01 Bestätigt SunTrust Buy
2018-09-26 Fortgesetzt JP Morgan Overweight
Alle ansehen

Lilly Eli Co Aktie (LLY) Neueste Nachrichten

pulisher
01:00 AM

Eli Lilly announces $1.50 Q2 dividend per share - Investing.com

01:00 AM
pulisher
12:56 PM

LLY stock news: Eli Lilly Declares $1.50 Quarterly Dividend - paginasiete.bo

12:56 PM
pulisher
12:49 PM

Eli Lilly & Co. (LLY) Declares $1.50 Quarterly Dividend; 0.7% Yield - StreetInsider

12:49 PM
pulisher
12:47 PM

Lilly declares second-quarter 2025 dividend - Yahoo Finance

12:47 PM
pulisher
06:45 AM

3 No-Brainer Stocks to Buy in May - The Motley Fool

06:45 AM
pulisher
05:21 AM

Eli Lilly’s Strategic Adjustments and Growth Prospects Reinforce Buy Rating Despite Setbacks - TipRanks

05:21 AM
pulisher
May 04, 2025

Eli Lilly First Quarter 2025 Earnings: EPS Misses Expectations - Yahoo

May 04, 2025
pulisher
May 04, 2025

Is the Trump Administration About to Cause AbbVie, Eli Lilly, and Johnson & Johnson Stocks to Crash? - Yahoo Finance

May 04, 2025
pulisher
May 03, 2025

This pill could forever change how people lose weight3 May 2025Time Magazine EuropeReadly | All magazines - Readly | All magazines - one magazine app subscription

May 03, 2025
pulisher
May 03, 2025

Eli Lilly and Company (NYSE:LLY) Q1 2025 Earnings Call Transcript - Insider Monkey

May 03, 2025
pulisher
May 02, 2025

Eli Lilly (LLY) Stock Rating Maintained by UBS Despite Price Tar - GuruFocus

May 02, 2025
pulisher
May 02, 2025

Eli Lilly (NYSE:LLY) Announces Promising Trial Data And Updates 2025 Guidance - Yahoo Finance

May 02, 2025
pulisher
May 02, 2025

UBS cuts Eli Lilly stock target to $1,050, maintains Buy rating - Investing.com UK

May 02, 2025
pulisher
May 02, 2025

Why Eli Lilly, Viking Therapeutics, and Novo Nordisk Stocks All Popped Friday - AOL.com

May 02, 2025
pulisher
May 02, 2025

Eli Lilly’s Stock Selloff Is Overdone, Analysts Say. Here’s Why. - MSN

May 02, 2025
pulisher
May 02, 2025

Cantor Fitzgerald maintains $975 target on Eli Lilly stock By Investing.com - Investing.com India

May 02, 2025
pulisher
May 02, 2025

Cantor Fitzgerald maintains $975 target on Eli Lilly stock - Investing.com

May 02, 2025
pulisher
May 02, 2025

Eli Lilly Stays Strong Despite CVS Dropping Key Drug - Finimize

May 02, 2025
pulisher
May 02, 2025

Leerink sees Eli Lilly stock dip as buying chance, keeps $944 target - Investing.com India

May 02, 2025
pulisher
May 02, 2025

Lilly to participate in Bank of America Securities 2025 Healthcare Conference - Quantisnow

May 02, 2025
pulisher
May 02, 2025

Eli Lilly CFO to Share Strategic Insights at Major Bank of America Healthcare Conference - Stock Titan

May 02, 2025
pulisher
May 02, 2025

Positive Outlook for Eli Lilly & Co. Despite Competitive Challenges - TipRanks

May 02, 2025
pulisher
May 02, 2025

Eli Lilly (LLY) Price Target Reduced by UBS Analyst Despite Stro - GuruFocus

May 02, 2025
pulisher
May 02, 2025

Eli Lilly (LLY) sell-off 'overdone' on CVS move on WegovyLeerink - StreetInsider

May 02, 2025
pulisher
May 02, 2025

Eli Lilly Tackles CVS Health's Cut In Zepbound Coverage - Finimize

May 02, 2025
pulisher
May 02, 2025

Street View: Eli Lilly well positioned in weight-loss market despite CVS's decision - TradingView

May 02, 2025
pulisher
May 02, 2025

Eli Lilly selloff on CVS Wegovy news overdone, says JPMorgan - TipRanks

May 02, 2025
pulisher
May 02, 2025

Eli Lilly & Co: Strong Market Position and Growth Potential Amid Competitive Pressures - TipRanks

May 02, 2025
pulisher
May 02, 2025

Decoding Eli Lilly and Co (LLY): A Strategic SWOT Insight - GuruFocus

May 02, 2025
pulisher
May 02, 2025

Eli Lilly and Co (LLY) Q1 2025 Earnings Call Highlights: Record Revenue Growth and Strategic ... - Yahoo Finance

May 02, 2025
pulisher
May 02, 2025

Eli Lilly and Co (LLY) Q1 2025 Earnings Call Highlights: Record Revenue Growth and Strategic Innovations - GuruFocus

May 02, 2025
pulisher
May 02, 2025

Eli Lilly (LLY) Faces Market Cap Drop Amid Competitive Pressure - GuruFocus

May 02, 2025
pulisher
May 02, 2025

Eli Lilly (LLY) Prepares for Potential Tariffs on Pharmaceuticals - GuruFocus

May 02, 2025
pulisher
May 02, 2025

Eli Lilly sales soar 45% on weight loss drug demand, but drugmaker cuts profit outlook after cancer treatment deal - MSN

May 02, 2025
pulisher
May 01, 2025

Eli Lilly downplays CVS move to drop Zepbound coverage, shares plunge - Reuters

May 01, 2025
pulisher
May 01, 2025

Friday Five – Pharma's tariff-proofing playbook, Novo slims Lilly's lead, vaccine policy shakeup…and more - FirstWord Pharma

May 01, 2025
pulisher
May 01, 2025

Obesity Drug Price Wars Heating Up as CVS Picks Novo Over Lilly - Bloomberg.com

May 01, 2025
pulisher
May 01, 2025

Lilly Cuts Earnings Guidance on Research Charges, Shares Fall - Bloomberg.com

May 01, 2025
pulisher
May 01, 2025

Eli Lilly (LLY) Stock: Shares Tumble 10% Despite 45% Revenue Surge in Q1 2025 - CoinCentral

May 01, 2025
pulisher
May 01, 2025

Eli Lilly and Company (LLY) Stock Price, News, Quote & History - Yahoo Finance

May 01, 2025
pulisher
May 01, 2025

CVS Drops Lilly’s Zepbound from Preferred Coverage in Novo Win - Bloomberg.com

May 01, 2025
pulisher
May 01, 2025

Eli Lilly Shares Tumble 10% After Q1 Earnings Miss Wall Street Estimates - Yahoo

May 01, 2025
pulisher
May 01, 2025

Eli Lilly (LLY) Gains WHO Support for Obesity Drug Zepbound - GuruFocus

May 01, 2025
pulisher
May 01, 2025

Eli Lilly downplays CVS move to drop Zepbound coverage, shares plunge By Reuters - Investing.com

May 01, 2025
pulisher
May 01, 2025

Is Eli Lilly and Company (LLY) the Best Growth Stock to Buy for the Next 3 Years? - Insider Monkey

May 01, 2025
pulisher
May 01, 2025

Eli Lilly CEO waves off CVS-Novo Nordisk deal: 'It feels a little like last decade' - Yahoo Finance

May 01, 2025
pulisher
May 01, 2025

Why Eli Lilly (LLY) Stock Is Nosediving - Yahoo Finance

May 01, 2025
pulisher
May 01, 2025

Eli Lilly, Microsoft Lead Market Cap Stock Movers on Thursday By Investing.com - Investing.com Nigeria

May 01, 2025
pulisher
May 01, 2025

Eli Lilly Earnings: Solid Performance Overshadowed by Novo’s Obesity Coverage Win - Morningstar

May 01, 2025
pulisher
May 01, 2025

Eli Lilly (NYSE:LLY) Reports Strong Q1 Growth Despite Lowered 2025 EPS Guidance - Yahoo Finance

May 01, 2025
pulisher
May 01, 2025

Eli Lilly, Microsoft Lead Market Cap Stock Movers on Thursday - Investing.com

May 01, 2025

Finanzdaten der Lilly Eli Co-Aktie (LLY)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
drug_manufacturers_general JNJ
$155.10
price down icon 0.67%
$195.49
price down icon 1.47%
drug_manufacturers_general NVO
$69.25
price up icon 0.01%
drug_manufacturers_general NVS
$113.05
price down icon 1.15%
drug_manufacturers_general MRK
$82.50
price down icon 0.81%
Kapitalisierung:     |  Volumen (24h):